Dr Ateeq has done path-breaking research on the resistance to androgen deprivation therapy, the mainstay treatment for prostate cancer patients. She showed that antiandrogen drugs used for the treatment of advanced-stage prostate cancer patients are actually detrimental in the long term, and Casein Kinase 1 inhibitors could be included as an adjuvant therapy for SPINK1-positive and neuroendocrine prostate cancer patients.